Sodji QH, Gutkin PM, Swetter SM, Reddy SA, Hiniker SM, Knox SJ. Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab.
Melanoma Manag 2020;
7:MMT36. [PMID:
32399174 PMCID:
PMC7212514 DOI:
10.2217/mmt-2019-0020]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2019] [Accepted: 01/31/2020] [Indexed: 12/12/2022] Open
Abstract
AIM
We previously reported a prospective trial evaluating the safety and efficacy of combining ipilimumab and radiation therapy in patients with metastatic melanoma. Herein, we provide a long-term update on patients with complete response (CR) or partial response (PR).
PATIENTS & METHODS
We continued to follow these patients with serial imaging including computed tomography, PET or MRI.
RESULTS
Two of the three patients with CR are still alive and without evidence of melanoma but with chronic treatment-induced hypophysitis. The third patient died of hepatocellular carcinoma, but with no evidence of melanoma. Among the three patients with PR, two achieved CR after pembrolizumab monotherapy.
CONCLUSION
This long-term follow up reveals the striking durability of the CRs, which appears to correlate with a grade 2-3 hypophysitis.
Collapse